Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Evaluating the effect of the angiotensin II-receptor (AT1) blocker candesartan vs placebo in
prevention of trastuzumab-associated cardiotoxicity in patients with primary breast cancer
treated with trastuzumab.
Phase:
Phase 3
Details
Lead Sponsor:
The Netherlands Cancer Institute
Collaborators:
AstraZeneca Roche Pharma AG
Treatments:
Angiotensin II Angiotensinogen Candesartan Candesartan cilexetil Trastuzumab